ClinicalTrials.gg
Active, not recruitingNCT04975776Updated Dec 23, 2025

Sleep Restriction Therapy for Insomnia in Primary Health Care

An interventional study of Sleep restriction therapy and Sleep hygiene in Insomnia, sponsored by Region Stockholm. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Region Stockholm · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden — 13 open to participants now, 15 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Sweden.

Planned enrollment
28th of 54
104 · median 105
Started
2022
with 1 other
No phase
42 of 58
11 open now
Primary completion
2027-08
later than 9 of 14 live
Registered
42nd of 58
by date
Lead sponsor
2 of 58
Region Stockholm

Among the 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden, this one is the 28th largest by planned enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2022, is one of 42 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 42nd registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

13 of the 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden, or all of them as a file.
02

Study summary

The recommended treatment for insomnia, cognitive behavioral therapy for insomnia (CBT-I), is effective. However, its long, multi-component nature makes it challenging to implement in ordinary primary care, where most people are treated. An important component of CBT-I is sleep restriction therapy, which may be comparatively easy to carry out in routine primary care. This project tests whether a brief nurse-led group intervention in primary care based on sleep restriction therapy for insomnia reduces insomnia severity and is cost-effective.

Read the detailed description

Background: Insomnia is typically treated in primary health care. The most common treatment is hypnotic drugs, despite their limited and short-term effects, the risk for adverse side effects and dependence, and the fact that CBT-I is the recommended first-line treatment. Reasons may include lack of knowledge about insomnia, a culture of prescribing hypnotics, lack of time during consultations, and a shortage of CBT-I providers. Sleep restriction therapy is one of the core components of CBT-I. It is a behavioral technique that may be feasible to deliver in routine care with existing resources and time constraints.

Objectives: This randomized controlled trial aims to investigate whether brief, behavioral group therapy in primary care based on sleep restriction therapy reduces insomnia severity and is cost-effective. A process evaluation will explore barriers and facilitators for participation and delivery.

Methods: Health care professionals from participating primary health care centers will complete a 1.5-day digital course on assessing patients for insomnia and delivering the intervention. Patients who seek primary health care and meet the study criteria will be randomized to sleep restriction therapy or to receive written sleep hygiene information. Both groups will be free to seek and receive standard care for insomnia. Sociodemographic and clinical characteristics will be collected prior to baseline. Study outcomes include insomnia severity, sleep, daytime symptoms, quality of life, use of hypnotics, sick leave, and work ability. Outcomes will be assessed over a 24-month period. The cost-effectiveness analysis will include the number of insomnia-free days at the 12-month follow-up and quality-adjusted life years. Patient characteristics will be analyzed in relation to adherence, and response. Qualitative explorations of patients and nurses' experiences will be conducted alongside the trial (approximately 15 patients and 15 nurses).

03

Conditions studied

  • Insomnia

Keywords

  • Disorders of Initiating and Maintaining Sleep
  • DIMS
  • Early Awakening
  • Awakening, Early
  • Nonorganic Insomnia
  • Insomnia, Nonorganic
  • Primary Insomnia
  • Insomnia, Primary
  • Transient Insomnia
  • Insomnia, Transient
  • Rebound Insomnia
  • Insomnia, Rebound
  • Secondary Insomnia
  • Insomnia, Secondary
  • Sleep Initiation Dysfunction
  • Dysfunction, Sleep Initiation
  • Dysfunctions, Sleep Initiation
  • Sleep Initiation Dysfunctions
  • Sleeplessness
  • Insomnia Disorder
  • Insomnia
  • Insomnias
  • Chronic Insomnia
  • Insomnia, Chronic
  • Psychophysiological Insomnia
  • Insomnia, Psychophysiological
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfills the diagnostic criteria for insomnia disorder: a) Difficulty initiating sleep, difficulty maintaining sleep, and early morning awakenings despite adequate opportunity for sleep (e.g., adequate time and circumstances for sleep and a safe, quiet, and dark bedroom). b) The sleep difficulties cause significant distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning. c) The sleep difficulties occur at least 3 nights per week and have been present for at least 3 months. d) The symptoms are not better explained by and do not occur exclusively during the course of another sleep-wake disorder. e) The symptoms cannot be attributed to the effects of a substance (e.g., drug abuse and medication). f) Coexisting mental disorders and medical conditions do not adequately explain the predominant complaint of insomnia.

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric illness (e.g., severe depression, schizophrenia, bipolar disorder)
  • Suicidal ideation
  • Untreated sleep disorder other than insomnia (e.g., sleep apnea, and restless legs syndrome)
  • Epilepsy
  • Cognitive disorder
  • Pregnancy
  • Night shift work
  • Language difficulties (inability to understand and speak Swedish well enough to participate in the intervention and respond to measurement instruments)
  • ≤ 7 points on the Insomnia Severity Index
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Sleep restriction therapy

    Four group sessions delivered at the participants' primary health care centers once a week for 3 weeks and again after a 4-week pause. The first session will last for 2 hours and the other sessions for 1 hour.

    Behavioral: Sleep restriction therapy

  • Active comparator
    Sleep hygiene

    Participants in the active comparator group will receive a brochure with sleep hygiene advice from the primary health care center at baseline.

    Behavioral: Sleep hygiene

Interventions

  • BehavioralSleep restriction therapy

    The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.

  • BehavioralSleep hygiene

    The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.

06

What researchers measure

Primary outcomes

  1. Change in Insomnia Severity Index (ISI) score

    The ISI is a 7-item scale that asesses the severity of sleep disturbance, how much sleep disturbance interferes with daily life and functioning, the noticeability of these impairments to others, worry and distress resulting from sleep disturbance, and general sleep satisfaction/dissatisfaction. Responses are provided on a Likert-scale (0-4). The total score ranges from 0 to 28, and higher scores indicate more severe problems.

    Time frame: Baseline and 3, 6, 12, and 24 months after baseline

Secondary outcomes

  1. Change in sleep efficiency derived from sleep diary

    Sleep efficiency (percentage of time asleep while in bed) will be calculated on the basis of self-reported sleep at each measurement point.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  2. Change in sleep onset latency derived from sleep diary

    Sleep onset latency (time to initiation of sleep after going to bed for the night) will be calculated on the basis of self-reported sleep at each measurement point.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  3. Change in time awake after sleep onset derived from sleep diary

    Time awake after sleep onset calculated on the basis of self-reported sleep at each measurement point.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  4. Change in number of nocturnal awakenings derived from sleep diary

    Number of nocturnal awakenings calculated on the basis of self-reported sleep at each measurement point.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  5. Change in sleep quality derived from sleep diary

    Perceived sleep quality will be calculated on the basis of self-reported sleep at each measurement point. The variable is rated on a Likert scale ranging from 1 to 5. Higher scores indicate better sleep quality.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  6. Change in Fatigue Severity Scale (FSS) score

    The FSS is a 9-item scale that measures the interference of fatigue with daily life. Each item is rated on a scale that ranges from 1 to 7. Higher total scores indicate more severe fatigue.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  7. Change in the Montgomery-Asberg Depression Rating Scale - self-rating version (MADRS-S) score

    MADRS-S includes 9 items that measure the severity of depressive symptoms (mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism, and zest for life). Each item includes six statements ranging from the most positive (statement 0) to the least positive (statement 6). The total score ranges from 0 to 54. The higher the score, the more severe the symptoms.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  8. Changes in the EQ-5D score

    EQ-5D is a generic measure of health status that measures quality of life in five health domains: mobility, self-care, daily activities, pain/suffering, and anxiety/depression. The response scale for each domain ranges from no problems (0) to severe problems (3). EQ-5D also includes a visual scale for each theme and for overall health status. Together, the responses form 248 different health profiles, each of which is assigned a point value that makes it possible to compare results.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  9. Changes in the Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) score

    DBAS measures dysfunctional beliefs and attitudes on an analog scale labeled "strongly disagree" to the left and "strongly agree" to the right. Respondents place a vertical mark at the point on the line that corresponds to degree that they disagree or agree with the statement. The distance (mm) from the left end of the line to the vertical mark is measured and used as the score. Scores range from 0 to 100. Higher scores indicate stronger agreement with the statement.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  10. Changes in Work Ability Index (WAI) score

    The WAI includes seven domains that measure current work ability compared with the lifetime best (0-10 points), work ability in relation to the demands of the job (2-10 points), number of current diseases diagnosed by a physician (1-7 points), estimated work impairment due to diseases (1-6 points), sickness leave during the past year (1-5 points), own prognosis of work ability two years from now (1, 4, or 7 points), and mental resources (1-4 points). The total score ranges from 7 to 49. Higher scores indicate better work ability.

    Time frame: Baseline, 1 year after baseline, and 2 years after baseline

  11. Changes in Short Form Health Survey-12 (SF- 12) score

    The SF-12 includes 12 items that measure health-related quality of life. The number of response alternatives varies by item. An algorithm is used to calculate final scores, which range from 0 to 100. Higher score indicate better quality of life.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  12. Change in Work and Social Adjustment Scale (WSAS) scores

    The WSAI is a 5-item scale that measures functional impairment related to sleep problems. Response alternatives range from 0 (not at all) to 8 (very severely). The total score ranges from 0 to 40. Higher scores indicate more severe impairment.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  13. Changes in self-reported hypnotic drug use

    A questionnaire that measures the frequency (including name and amount taken) of the use of prescribed hypnotics on a Likert scale ranging from never (1) to daily (6). Higher scores indicate more frequent use.

    Time frame: Baseline and 3, 12, and 24 months after baseline

  14. Changes in self-reported sick leave

    Participants will be asked to report the number of days they have been on sick leave.

    Time frame: Baseline, 1 year after baseline, and 2 years after baseline

  15. Treatment side effects

    Participants will complete a questionnaire that includes 10 items that measure the perceived severity of potential side effects of sleep restriction therapy on a Likert scale. The scores range from 1 to 4. Higher scores indicate more severe side effects. The questionnaire also includes a question asking about the time for side effects (e.g., in the beginning of treatment, mid-treatment etc.).

    Time frame: 3 months after baseline

  16. Treatment adherence

    Participants will complete a questionnaire that includes nine items that measure self-rated adherence to sleep restriction therapy on a Likert scale. Higher scores indicate better adherence. The score on each item range from 1 to 4.

    Time frame: 3 months after baseline

07

Study locations

1 site
  • Christina Sandlund
    Stockholm, Stockholms Läns Landsting 104 31, Sweden
08

References and documents

Publications

  • Maurer LF, Schneider J, Miller CB, Espie CA, Kyle SD. The clinical effects of sleep restriction therapy for insomnia: A meta-analysis of randomised controlled trials. Sleep Med Rev. 2021 Aug;58:101493. doi: 10.1016/j.smrv.2021.101493. Epub 2021 Apr 21. PubMed 33984745 ↗
  • Kyle SD, Morgan K, Spiegelhalder K, Espie CA. No pain, no gain: an exploratory within-subjects mixed-methods evaluation of the patient experience of sleep restriction therapy (SRT) for insomnia. Sleep Med. 2011 Sep;12(8):735-47. doi: 10.1016/j.sleep.2011.03.016. Epub 2011 Sep 9. PubMed 21907616 ↗
  • Sandlund C, Hetta J, Nilsson GH, Ekstedt M, Westman J. Improving insomnia in primary care patients: A randomized controlled trial of nurse-led group treatment. Int J Nurs Stud. 2017 Jul;72:30-41. doi: 10.1016/j.ijnurstu.2017.03.007. Epub 2017 Apr 14. PubMed 28445790 ↗
  • Sandlund C, Kane K, Ekstedt M, Westman J. Patients' experiences of motivation, change, and challenges in group treatment for insomnia in primary care: a focus group study. BMC Fam Pract. 2018 Jul 9;19(1):111. doi: 10.1186/s12875-018-0798-2. PubMed 29986651 ↗
  • Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Goncalves M, Hertenstein E, Jansson-Frojmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Weess HG, Wichniak A, Zavalko I, Arnardottir ES, Deleanu OC, Strazisar B, Zoetmulder M, Spiegelhalder K. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017 Dec;26(6):675-700. doi: 10.1111/jsr.12594. Epub 2017 Sep 5. PubMed 28875581 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Aug 2027, 66 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 66 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2021
First posted
Jul 23, 2021
StartActual
Feb 1, 2022
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04975776
Lead sponsor
Region Stockholm
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Feb 1, 2022
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Dec 23, 2025

Study contacts

Christina Sandlund, PhD
principal investigator · Region Stockholm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion